2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
Case Study: How Shire improved its time-to-marketAdopting an end-to-end commercial content management system has allowed one of the world’s biggest pharmaceutical companies to be Share XCase Study: How Shire improved its time-to-markethttps://pharmaphorum.com/debates-insight-sales-marketing/case-study-how-shire-improved-its-time-to-market/
Takeda mulling sale of emerging market drugs – reportTakeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Share XTakeda mulling sale of emerging market drugs – reporthttps://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
Takeda’s Shire takeover could herald new era of pharma M&ATakeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in Share XTakeda’s Shire takeover could herald new era of pharma M&Ahttps://pharmaphorum.com/news/takedas-shire-takeover-could-herald-new-era-of-pharma-ma/
Takeda unlikely to sell OTC unit to pay Shire merger debtsTakeda’s $59 billion takeover of Shire is due to close tomorrow (Tuesday) and the company’s CEO Christophe Weber Share XTakeda unlikely to sell OTC unit to pay Shire merger debtshttps://pharmaphorum.com/news/takeda-unlikely-to-sell-otc-unit-to-pay-shire-merger-debts/
Shareholders approve Takeda’s $59bn takeover of ShireTakeda’s $59 billion acquisition of Shire has been backed by shareholders from both companies, clearing the way for Share XShareholders approve Takeda’s $59bn takeover of Shirehttps://pharmaphorum.com/news/shareholders-approve-takedas-59bn-takeover-of-shire/
Gene therapy firm BioMarin stages haemophilia musicalBioMarin Pharmaceutical has put on a stage musical to raise awareness about haemophilia, and determine whether creative expression Share XGene therapy firm BioMarin stages haemophilia musicalhttps://pharmaphorum.com/news/gene-therapy-firm-biomarin-stages-haemophilia-musical/
Takeda must sell gastro drug to merge with Shire – EU regulatorsEuropean regulators have officially rubber stamped Takeda’s $62 billion takeover of Shire, although the merged company will have Share XTakeda must sell gastro drug to merge with Shire – EU regulatorshttps://pharmaphorum.com/news/takeda-must-sell-gastro-drug-to-merge-with-shire-eu-regulators/
